No idea, but I would assume definitely not in this current market environment. CHM and RAD IPOed during the Bio-Boom and got dragged down like most non-income producing bio-techs. But maybe he takes on ALA which is run by M.Baker, a director of RAD, and IMU is advancing ALA's iNKT platform which he brought to SUD / ALA.
He got enough to do to turn the 3/4 comps around, hardly to think he starts up another one at this stage. Plus the 3/4 comps tackle solid cancers, with a virus, CAR-T applications and radiation. Plenty of opportunities with the 3/4 ones.
Sadly the morning run got turned down due to China and US FED-jitters.
GLTA
CHM Price at posting:
4.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)